Gaps in the level of Hemoglobin A1C, BP, and LDL-Cholesterol reduction continue to occur in high-risk individuals with Type 2 diabetes, Hypertension, and Dyslipidemia, respectively. Recent results from the ACCORD, VADT, and ADVANCE studies suggest the benefits on reducing macrovascular disease events are unclear and, in fact, caution should be exercised when reducing Hemoglobin A1C in those with long standing Type 2 diabetes to a goal of 6% when compared to a goal between 7 and 7.9%. In addition, controversy continues from recent guidelines on the level of LDL-cholesterol and BP reduction that can be and should be achieved. This conference will address these and other issues confronting the clinician who treats patients with diabetes, hypertension, and dyslipidemia. The participant will learn the most current information on these issues and will be able to transport thee clinical principles back to their every day practice to improve patient care.